热门资讯> 正文

AbbVie标记了第三季度2.16亿美元的IPR&D和里程碑费用

2026-10-06 05:04

AbbVie (ABBV) said its Q3 financial results will likely include an acquired in-process research and development (IPR&D) and milestones expense of $216M on a pre-tax basis.
As a result, GAAP and non-GAAP diluted EPS will be negatively impacted by $0.11.
With the IPR&D and milestone expenses considered, AbbVie projects full-year adjusted diluted EPS of $13.76—$13.96 (consensus $14.01) and Q3 adjusted diluted EPS of $3.73—$3.77 (consensus $3.84).

More on AbbVie

AbbVie: Revenue Pressure And Weakening Earnings Support A 'Sell'
2026 2H Healthcare Dividend Roundup: Johnson & Johnson Outshines AbbVie
AbbVie Inc. (ABBV) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Genmab, AbbVie data boosts Epkinly as first-line B-cell lymphoma treatment
AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。